The ANXA1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ANXA1 gene in the human A-549 lung adenocarcinoma cell line. This product provides a heterogeneous loss-of-function model for investigating the roles of annexin A1 in pulmonary epithelial biology and disease. The polyclonal format, generated by CRISPR/Cas9-mediated gene disruption, maintains a broad representation of editing events across the target locus, enabling robust functional studies without single-cell clone selection. Researchers can immediately apply this knockout model to explore ANXA1-dependent cellular processes in alveolar type II-like epithelial cells.
The parental A-549 cell line, derived from a 58-year-old Caucasian male with lung adenocarcinoma, serves as a widely used model for lung adenocarcinoma and respiratory epithelium function. These cells exhibit characteristics of alveolar type II pneumocytes, including surfactant production and epithelial barrier properties, making them highly relevant for studying lung cancer pathobiology, inflammatory signaling, and epithelial-mesenchymal interactions. The cell line??s well-characterized genetic background and responsiveness to steroidal and growth factor stimuli provide a reliable platform for examining ANXA1 function in a clinically relevant context.
Annexin A1 (ANXA1) is a calcium-dependent phospholipid-binding protein that acts as a central mediator of glucocorticoid-regulated anti-inflammatory responses. Upstream regulators such as glucocorticoids (via the glucocorticoid receptor NR3C1), IL-6, EGF, and TGF-?? control ANXA1 expression and activity. Upon activation, ANXA1 is recruited to the cell surface and secreted, where it signals in an autocrine or paracrine manner through the FPR2/ALX receptor. Downstream effects include inhibition of cytosolic phospholipase A2 (cPLA2), modulation of MAPK1/3 (ERK1/2) and NF-??B pathways, and regulation of apoptosis-related factors such as Bcl-2 and caspase-3. Additionally, ANXA1 interacts with S100A11, EGFR, actin, and annexin A2, forming multi-protein complexes that influence membrane trafficking, EGFR transactivation, and cytoskeletal reorganization. These molecular interactions position ANXA1 at the intersection of glucocorticoid receptor signaling, EGFR/ErbB signaling, MAPK/ERK cascades, NF-??B inflammatory responses, and Wnt/??-catenin pathways.
Disruption of ANXA1 in A-549 cells is anticipated to enhance pro-inflammatory signaling and alter tumor cell behavior, given its role in suppressing NF-??B and MAPK/ERK activity. Without functional ANXA1, pathways downstream of glucocorticoids and growth factors may be dysregulated, leading to increased secretion of inflammatory cytokines, altered apoptosis kinetics, and modified cell migration and invasion capabilities. This knockout model thus provides a valuable system for dissecting how ANXA1 integrates anti-inflammatory and pro-survival signals in lung adenocarcinoma, and for exploring mechanisms of glucocorticoid resistance??a clinically significant challenge in non-small cell lung cancer and chronic inflammatory lung diseases.
These polyclonal ANXA1 knockout cells are suitable for a range of research applications, including detailed molecular dissection of glucocorticoid anti-inflammatory mechanisms in lung epithelium, investigation of ANXA1-mediated regulation of cancer cell proliferation and metastasis, and high-throughput screening for glucocorticoid sensitivity modulators. Typical workflows include Western blotting to assess ANXA1, phosphorylated ERK1/2, and NF-??B subunit expression; RT-qPCR profiling of inflammatory cytokine mRNAs (IL-6, IL-8); immunofluorescence localization studies; flow cytometric apoptosis analysis using annexin V/propidium iodide staining; Boyden chamber migration and invasion assays; luciferase reporter assays for NF-??B transcriptional activity; and glucocorticoid response experiments with dexamethasone treatment. For technical inquiries and ordering information, please contact Ascent Research.
The ANXA1 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population targeting the annexin A1 gene in the A-549 human lung adenocarcinoma cell line. Annexin A1 is a pivotal mediator of glucocorticoid-induced anti-inflammatory signaling, regulating MAPK/ERK and NF-??B pathways through interactions with the FPR2/ALX receptor and cPLA2. This knockout model in alveolar type II-like epithelial cells enables investigation of ANXA1 functions in lung cancer progression, glucocorticoid resistance, and inflammatory lung diseases such as asthma and inflammatory bowel disease. Applications include Western blotting, RT-qPCR, immunofluorescence, apoptosis assays, migration studies, and NF-??B reporter analysis to explore mechanisms of tumor cell behavior and anti-inflammatory signaling.
